These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 6985117)

  • 1. [Oral bioavailability of an L-5-HTP/carbidopa tablet].
    Obach R; Pruñonosa J; Vallés J; Vallés JM
    Arch Farmacol Toxicol; 1982 Dec; 8(3):179-82. PubMed ID: 6985117
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
    Smarius LJ; Jacobs GE; Hoeberechts-Lefrandt DH; de Kam ML; van der Post JP; de Rijk R; van Pelt J; Schoemaker RC; Zitman FG; van Gerven JM; Gijsman HJ
    J Psychopharmacol; 2008 Jun; 22(4):426-33. PubMed ID: 18308795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of carbidopa on the cerebral accumulation of exogenous L-5-hydroxytryptophan in mice.
    Magnussen I
    Acta Pharmacol Toxicol (Copenh); 1984 Sep; 55(3):199-202. PubMed ID: 6334429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects.
    Byerley WF; Judd LL; Reimherr FW; Grosser BI
    J Clin Psychopharmacol; 1987 Jun; 7(3):127-37. PubMed ID: 3298325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of l-5-hydroxytryptophan in healthy subjects.
    Westenberg HG; Gerritsen TW; Meijer BA; van Praag HM
    Psychiatry Res; 1982 Dec; 7(3):373-85. PubMed ID: 6187038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How physician obesity specialists use drugs to treat obesity.
    Hendricks EJ; Rothman RB; Greenway FL
    Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the bioavailability of Redergin tablets (1.0 mg) and Redergin solution.
    Kopitar Z; Milovac J; Vrhovac B; Tadjer I
    Int J Clin Pharmacol Ther Toxicol; 1982 Mar; 20(3):134-8. PubMed ID: 7068286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state.
    Magnussen I; Nielsen-Kudsk F
    Acta Pharmacol Toxicol (Copenh); 1980 Apr; 46(4):257-62. PubMed ID: 6966118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
    Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
    Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic profile of carbidopa in dogs.
    Obach R; Menargues A; Vallès JM
    J Pharm Pharmacol; 1984 Jun; 36(6):415-6. PubMed ID: 6146680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, bioavailability, and dosage regimens of digoxin in dogs.
    Button C; Gross DR; Johnston JT; Yakatan GJ
    Am J Vet Res; 1980 Aug; 41(8):1230-7. PubMed ID: 7447117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Improvement of ophthalmoplegia by 5-hydroxytryptophan in two cases of progressive supranuclear palsy].
    Yukitake M; Takashima Y; Kurohara K; Matsui M; Kuroda Y
    Rinsho Shinkeigaku; 1996 Jul; 36(7):906-8. PubMed ID: 8952364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of fixed dose combination tablets containing zidovudine and lamivudine for paediatric applications.
    Kayitare E; Vervaet C; Ntawukulilyayo JD; Seminega B; Bortel V; Remon JP
    Int J Pharm; 2009 Mar; 370(1-2):41-6. PubMed ID: 19059324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.
    Turner EH; Loftis JM; Blackwell AD
    Pharmacol Ther; 2006 Mar; 109(3):325-38. PubMed ID: 16023217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V; Oliver S; Su CA
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food.
    Marathe PH; Arnold ME; Meeker J; Greene DS; Barbhaiya RH
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1494-502. PubMed ID: 11185672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.